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Steffen Walter18, Ena Wang10 and John Waslif19Abstract: While there has been significant progress in advancing novel immune therapies to the bedside, much
more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that
besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current
immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches
point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series
sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership
from academia and industry, to identify, share and discuss most current priorities in research and translation of
novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines
the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.While there has been progress in translating immune
interventions from the bench to the bedside – most not-
ably monoclonal antibodies and second generation anti-
body drug conjugates (ADC) [1] – much more needs to
be done to leverage the immune system in the fight
against cancer. With the advent of checkpoint blockade
antibodies such as the approval of anti-CTLA4 mono-
clonal antibody Yervoy™ (Ipilumumab)W [2], PD-1/PD-L
blocking molecules in development [3] and the previous
approval of the autologous cellular immunotherapy
ProvengeW, (Sipuleucel-T) [4], we are entering a new era
of rapid diversification of the platform technologies that
carry significant promise to change the standard of care
in cancer. Key to this aspect is to identify targets and
optimize approaches that mobilize the immune system
safely and effectively to provide long-term control of dis-
ease in the adjuvant or post-therapy minimal residual
disease, as well as in advanced, metastatic setting.
A recently published, highly accessed collaborative re-
view [5], identified nine major hurdles in effectively* Correspondence: abot@kitepharma.com
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reproduction in any medium, provided the ordesigning and translating novel immune interventions
for cancer, including the limited predictive value of pre-
clinical modeling, the complexity of cancer and immune
escape mechanisms reflected in the need for combin-
ation therapies, scarcity of reliable predictive and
pharmacodynamics biomarkers, along with regulatory,
budgetary and operational bottlenecks. Some of these
scientific and technical hurdles were also discussed in
more detail at a summit organized by Arrowhead Pub-
lishers and Conferences, the first in a recurring series,
entitled “The World Cancer Immunotherapy Confer-
ence: Challenges and Opportunities in Clinical Develop-
ment, Clinical Trial Design and Commercialization”
which took place on January 25–26, 2012 in San Diego,
CA (http://www.cancervaccinesconference.com/). This
event brought together a focused group of key scientists
and industry leadership from across the globe to share
research, case studies and viewpoints on various topics
integral to a better understanding of the challenges and
opportunities facing developers of therapeutic cancer
vaccines and immune interventions in general. The
selected topics derived from five questions with a highly
pragmatic connotation:. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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immunotherapies, both from the standpoint of
response rate and durability?
2. What are the feasible strategies for integrating
immunotherapy with other treatments ?
3. How do we limit the high failure rate in late stage
clinical development ?
4. What is the significance and value of immune
monitoring ?
5. How do we identify and effectively utilize lessons
learned from past challenges in clinical and
commercial settings ?
Optimization of the current product development pro-
cesses must benefit from prior experience especially with
immunotherapies that underwent a successful cycle
reaching commercialization. Dr. Candice McCoy from
Dendreon Corp. outlined challenges and lessons learned
from the clinical development and approval process for
ProvengeW. In addition to sharing clinical trial results
and regulatory milestones, she discussed items of critical
importance for bringing an exceedingly complex immu-
notherapeutic product to market: the need for immune
response assessment that is relevant to the mechanism
of action, and for the development of potency assay bio-
markers starting early in development so that during
late-stage clinical trials appropriate release testing ac-
companied by sound acceptance criteria can be vali-
dated, a pre-requisite for successful licensing.
Predictive biomarker discovery and translation to com-
panion diagnostics to identify patients with a higher like-
lihood of benefitting from immunotherapy could make
the difference between a viable and a non-viable product
in both the clinic and market place. This important
undertaking addresses the tremendous heterogeneity of
the neoplastic molecular mechanisms, host genetic poly-
morphisms of the immune system and other controllers
of malignancy, and demographic factors that impact the
occurrence of common and rare cancers. Dr. Vincent
Brichard from GSK Biologicals, while providing an up-
date on the status of the pivotal MAGRIT and DERMA
trials utilizing adjuvanted recombinant MAGE-A3 pro-
tein as a therapeutic vaccine, highlighted the potentially
critical value of immune gene signatures as predictive
markers and co-primary endpoints along with disease-
free survival. Meeting the clinical efficacy endpoints in
patient populations identified by this signature would
break novel grounds in immunotherapy, and translate to
market a recombinant protein based cancer vaccine ac-
companied by a diagnostic indicator.
Dr. Richard Harrop from Oxford BioMedica provided
a retrospective analysis of the phase III trial with the
TroVaxW (MVA-5T-4) therapeutic vaccine in renal can-
cer patients. While the overall trial results did not meetthe primary endpoints, they enabled a detailed investiga-
tion of early predictors of treatment benefit such as
tumor antigen 5T4-specific antibodies. Markers in this
category are needed for treatments that may have a
delayed impact on the disease or may benefit only sub-
sets of patients who can be defined prior to therapy. The
results from the trial appeared to corroborate the value
of the mean corpuscular hemoglobin concentration
(MCHC), a commonly-reported clinical laboratory value,
as a predictor of clinical benefit for the addition of
MVA-5T4 vaccine to standard Sunitinib or cytokine
therapy. This inflammatory marker and others repre-
senting the tumor, treatment, and host interactions will
require validation in subsequent trials.
Dr. Steffen Walter from Immatics Biotechnologies,
discussed how biomarkers have been utilized to guide
clinical development of their GM-CSF-adjuvanted multi-
peptide renal and colorectal cancer vaccines, including
the investigation of cyclophosphamide in conjunction
with vaccination, based on previous observations nega-
tively correlating the presence and number of T regula-
tory (Treg) cells with the immune response upon
vaccination. The much-debated and diverse topic of
biomarkers was discussed in a panel session co-chaired
by Drs. Walter and Francesco Marincola of the NIH,
entitled “Biomarkers and Cancer Immunotherapies:
Measuring success in clinical development”.
Immunologic monitoring is in itself a vast arena within
the realm of biomarkers, as the immune response is a
personalized and multifaceted response to the tumor as
well as any intervention being tested. The complexity of
this area as well as a wide range of scientific and tech-
nical approaches to it, have led to controversy as to cor-
relations between measures of immunity and clinical
outcomes. Dr. Lisa Butterfield from the University of
Pittsburgh Cancer Institute, first provided an update on
current immunotherapy clinical trials conducted in
hepatocellular carcinoma and melanoma with a variety
of vaccine approaches, based on lessons learned from
previous immunologic monitoring. She then highlighted
the concept that a broad and diverse immune response
score encompassing the breadth of response against
multiple antigens with evidence of determinant spread-
ing, functionality and co-induction of both T helper and
cytotoxic lymphocytes, could be a superior correlate of
clinical activity in the face of patient and therapeutic ap-
proach heterogeneity. Dr. Graham Pawelec, from the
University of Tübingen Medical School, showed a very
interesting direct relationship between long term sur-
vival of melanoma patients and immunity against differ-
ent tumor antigens demonstrated by functional T cell
assays in vitro, irrespective of the patients treatment.
While the CD8 T cell response against Melan A/MART-
1 and NY-ESO-1 were directly correlated with survival
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Melan-A/MART-1 mitigated against long-term survival,
presumably due to selective activation of regulatory T
cells. Dr. Francesco Marincola, in his presentation
entitled “Focusing immune monitoring where it matters:
the tumor site” discussed a cluster of pivotal genes
expressed within the tumor and associated with tumor
regression by immune mechanisms (“immunological
constant of regression”). In addition, he provided evi-
dence that IRF-1 is a key switch deploying acute rather
than chronic inflammation, resulting in tumor regression
rather than progression. Both Drs. Marincola and Ena
Wang of the NIH discussed their tantalizing discovery
that IRF-5 polymorphism is associated with clinical
benefit afforded by adoptive T cell therapy, a platform
technology that allows rapid progress in discovering of
immune correlates of protection by virtue of its
increased rate of clinical response. Illustrating the pro-
gress of evaluating various vaccine technologies in the
clinical development stage, there were several presenta-
tions on topics spanning autologous cell-based, viral and
peptide-based vaccines in phase II and III clinical trials.
Drs. John Rothman, Advaxis Inc and Dirk Brockstedt,
Aduro Biotech, highlighted the progress with their dis-
tinct Listeria vaccines aimed at treating different solid
cancers. Dr. Rothman outlined the evidence to date on
their HPV E7-directed vaccine for advanced cervical car-
cinoma, grounds for the initiation of a randomized trial
in combination with platinum-based chemotherapy. Dr.
Brockstedt discussed a different clinical strategy, bring-
ing a Listeria vector attenuated by distinct genetic means
and expressing the tumor antigen mesothelin to phase II
trials in pancreatic carcinoma, using a heterologous
prime-boost approach. Dr. Marnix Bosch, Northwest
Biotherapeutics Corp., presented his company’s program
advancing the DC-based platform technology primarily
in advanced clinical trials in glioblastoma multiforme,
with exciting new collaborative efforts exploring integra-
tion of DC vaccines with adoptive T cell therapy in ovarian
carcinoma, and direct intra-tumoral injection of mature
DC in head and neck cancer and other inoperable tumors.
Dr. Mark Ahn, Galena Biopharma, described the progress
of NeuVax™ (nelipepimut-S), a nonapeptide Her2/Neu
oncogene product delivered intradermally in the minimal
residual disease setting. Based on successful phase II,
NeuVax is being developed in a Phase III with a Special
Protocol Assessment (SPA), as an adjuvant immunother-
apy to prevent or delay recurrence for women with
early-stage high risk (node positive) HER2 negative (IHC
1+/2+) breast cancer.
As is now evident, vaccines are being explored more
and more as combination approaches with agents that
are already part of standard of care or other interven-
tions that have immune modulating potential. This is fortwo reasons: to increase vaccine efficacy in the clinic
and secondly, to accomplish application in earlier dis-
ease stages for both scientific and commercial reasons.
Dr. Jeffrey Schlom, NIH, developed this aspect in his
presentation entitled “Recombinant vector cancer vac-
cines as monotherapy and in combination therapies”
utilizing TRICOM vaccinia vector co-expressing im-
mune stimulatory molecules as a representative example,
in context of a rapidly evolving field [6]. Dr. Kim Margolin,
of the University of Washington School of Medicine, out-
lined the emerging collaborative efforts of “The Cancer Im-
munotherapy Trials Network” (CITN) to match the highest
priority immune-modulating compounds with promising
vaccines or immune interventions, offering a novel frame-
work for testing combination immunotherapies.
A number of speakers discussed new and promising
technologies, adjuvants and targets. Dr. W. Martin Kast
of the University of Southern California presented his
efforts and exciting preclinical evidence in support of
heterologous prime-boost vaccines encompassing gen-
etic and vectors expressing strong adjuvants such as
LIGHT, which mobilizes immunity within tumors [7].
Dr. Tereza Ramirez-Montagut, of the Genomics Insti-
tute of the Novartis Research Foundation, introduced
her organization’s efforts to develop more potent
vaccine-based technologies that employ modified anti-
gens that incorporate unnatural amino acids and novel
TLR agonists. Michael Cross, of OncoSec Medical Inc.,
described the efforts to advance an in vivo electropor-
ation device applicable to tumors that are superficial but
could have metastatic manifestations. The device, in
conjunction with IL-12 plasmid utilization, is entering
later clinical trial stages in melanoma, cutaneous T cell
lymphoma and Merckel cell carcinoma. Dr. Pramod
Srivastava, of the University of Connecticut Health
Center, outlined a new concept, utilization of high per-
formance genomics to rapidly discover a personalized
“immunome” – a collection of potentially immunogenic
antigens and epitopes – that could be turned around
rapidly into a truly personalized vaccine. The facilitating
elements in support of such technologies are becoming
more feasible, thus creating the premises for such a per-
sonalized approach sooner rather than later.
Tumor-initiating cells (“cancer stem cells”) are the
topics of much debate and considered to represent cellu-
lar targets amenable to immune interventions. Dr.
Andrew Cornforth of California Stem Cell, presented his
organization’s efforts to translate a program based on
rapidly proliferating tumor cells isolated in vitro, in con-
junction with autologous dendritic cells and GM-CSF
for melanoma. Dr. Jeffrey Schlom from the NIH intro-
duced a novel target, Brachyury, involved in the
epithelial-to-mesenchymal transition (EMT), cancer cell
”stemness” and drug resistance. Dr. Richard Koya of the
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exciting emerging approach, utilizing genetic engineer-
ing and adoptive transfer of T cells for treatment of solid
tumors such as melanoma. Promising clinical data, hur-
dles and opportunities to integrate this approach with
other therapies, especially novel FDA-approved inhibi-
tors of the MAPK signaling to achieve durable manage-
ment of cancer, were also discussed.
Last but not least – and reflecting the pragmatic focus
of the summit – Mara Goldstein, Senior Healthcare
Analyst with Cantor Fitzgerald, provided “An Investor's
Perspective on Cancer Immunotherapy Research & De-
velopment”. Her discussion highlighted that investors
are gradually becoming more optimistic, reflected by an
environment in which initial public offerings and finan-
cing in general are possible and even oversubscribed, yet
often discounted.
As is apparent from the above report, the field of
cancer immunotherapy is rapidly expanding and divers-
ifying; thus Arrowhead Publishers and Conferences is
now organizing the 2nd Annual Arrowhead Cancer
Immunotherapy Conference that will occur on April
4-5th, 2013, in the Washington DC area (http://www.
cancervaccinesconference.com/). More details of this
event will be released shortly, but the overall theme will
be “Stem Cells and Cancer Immunotherapy”. The first
track will cover tumor initiating or “cancer stem cells” as
a new category of targets for immune intervention and
drug development. Recent breakthrough evidence is in
strong support of the concept of cell “stemness” in solid
tumors [8-10] and stem cell-directed immunotherapy as
an alternate and potentially more effective approach to
tackle cancer [11]. In this track, speakers will be cover-
ing biology and identification of cancer stem cells or
tumor initiating cells, and associated targets amenable to
a variety of platforms including antibodies, vaccines or
cells.
The second track will be dedicated to lymphoid and
hematopoietic stem cells that have demonstrated a
therapeutic potential in the context of genetic engineer-
ing of the immune system and adoptive T cell therapy
[12,13]. This approach carries the considerable potential
of effectively halting the progression of cancer in its lat-
est stage, and the most important tasks ahead are how
to control its safety and efficacy, along with increasing
its feasibility. The key ingredients for the next stage in
development of this approach are becoming more avail-
able as the realization that a new artificial immune
repertoire – with reactivity against cancer antigens - could
be engrafted by genetic means and stem cells onto the
natural immune repertoire that evolved primarily as an
anti-infectious rather than anti-cancer defense mechanism.
The practical question of how to effectively harness renew-
able army of anti-tumor effector cells, at the time and placeneeded, awaits appropriate solutions as this will be crucial
for safety and efficacy. Thus, in this track, speakers will be
covering aspects related to the translation of adoptive T cell
therapies and strategies to redesign the immune system
through genetically-engineered hematopoietic stem cells or
“stem cell-like memory cells”.
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